Premature Labor (Tocolysis) - Pipeline Review, H1 2014

Premature Labor (Tocolysis) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Pipeline Review, H1 2014’, provides an overview of the Premature Labor (Tocolysis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premature Labor (Tocolysis) Overview 6
Therapeutics Development 7
Pipeline Products for Premature Labor (Tocolysis) - Overview 7
Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 8
Premature Labor (Tocolysis) - Therapeutics under Development by Companies 9
Premature Labor (Tocolysis) - Pipeline Products Glance 10
Clinical Stage Products 10
Premature Labor (Tocolysis) - Products under Development by Companies 11
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 12
GlaxoSmithKline plc 12
Actavis plc 13
Kissei Pharmaceutical Co., Ltd. 14
PDC Biotech GmbH 15
Ferring Pharmaceuticals, Inc. 16
Premature Labor (Tocolysis) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
retosiban - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
bedoradrine sulfate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
barusiban - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PDC-31 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
progesterone Vaginal Gel Second Generation - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Premature Labor (Tocolysis) - Recent Pipeline Updates 33
Premature Labor (Tocolysis) - Dormant Projects 36
Premature Labor (Tocolysis) - Discontinued Products 37
Premature Labor (Tocolysis) - Product Development Milestones 38
Featured News & Press Releases 38
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 38
Oct 17, 2012: Progesterone Drug Fails To Prevent Preterm Birth In High Risk Group, NIH Study Shows 38
Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8% 39
Feb 09, 2012: Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories 40
Jan 20, 2012: FDA Advisory Committee Declines To Recommend Approval Of Watson's Progesterone Vaginal Gel 8% For Reduction Of Risk Of Preterm Birth In Women With Short Uterine Cervical Length 40
Nov 10, 2011: Columbia Laboratories And Watson Pharmaceuticals Confirm FDA Advisory Committee To Review Preterm Birth NDA 41
Jun 27, 2011: Columbia Laboratories' NDA For PROCHIEVE Vaginal Progesterone Gel Accepted For Filing By FDA 41
Apr 26, 2011: Columbia Laboratories Submits NDA For PROCHIEVE Vaginal Progesterone Gel 42
Apr 06, 2011: NIH Study Finds Progesterone Reduces Rate Of Early Preterm Birth In At Risk Women 42
Apr 06, 2011: Columbia And Watson Announce Publication Of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H1 2014 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Products under Development by Companies, H1 2014 11
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2014 12
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2014 13
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 14
Premature Labor (Tocolysis) - Pipeline by PDC Biotech GmbH, H1 2014 15
Premature Labor (Tocolysis) - Pipeline by Ferring Pharmaceuticals, Inc., H1 2014 16
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Stage and Target, H1 2014 19
Number of Products by Stage and Mechanism of Action, H1 2014 21
Number of Products by Stage and Route of Administration, H1 2014 23
Number of Products by Stage and Molecule Type, H1 2014 25
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2014 33
Premature Labor (Tocolysis) - Dormant Projects, H1 2014 36
Premature Labor (Tocolysis) - Discontinued Products, H1 2014 37

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H1 2014 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Top 10 Target, H1 2014 18
Number of Products by Stage and Top 10 Target, H1 2014 19
Number of Products by Top 10 Mechanism of Action, H1 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 21
Number of Products by Top 10 Route of Administration, H1 2014 22
Number of Products by Stage and Top 10 Route of Administration, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25